Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review.

For example, in the randomized phase II clinical trial comparing bevacizumab alone or in combination with irinotecan in 167 patients with recurrent, treatment-refractory GBM [ 61 ], patients who were taking corticosteroids at baseline showed a trend to take stable or decreasing doses over time, e.g., median corticosteroid dose was reduced by about 75% after 6 months (Fig. 1 ).

also in 53,322 other papers